Course Description
About AAPP Toolkits
AAPP toolkits highlight both the evidence base available as well as strategies of clinical decision making used by expert psychiatric pharmacist clinicians. The content reflects the views and practice of the authors as substantiated with evidence-based facts as well as opinion and experience. Toolkits are peer reviewed by psychiatric pharmacists. Authors and AAPP review and update toolkits annually and strive to use up-to-date, non-stigmatizing language. Terminology does evolve rapidly and often regionally such that there may be differences between reader experiences and expectations and those of the author(s). AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
Xylazine is a nonopioid veterinary anesthetic that is increasingly detected in the illicit drug supply across the United States. Among opioid-overdose deaths, there has been a dramatic increase in the presence of xylazine. It is now a common additive to substances like fentanyl, heroin and cocaine. Fentanyl Adulterated or Associated with Xylazine (FAAX) was declared an emerging threat on April 12, 2023 by the White House Office of National Drug Control Policy.
Authored by AAPP member Sarah Thomason, PharmD, BCPP, BCACP, FASCP, contents of this pharmacist toolkit include:
- Current Trends
- Street Names
- Pharmacology/Pharmacokinetics
- Harm Reduction
- References